A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma

被引:1
|
作者
de la Serna, Celia Diez de los Rios [1 ]
Drury, Amanda [2 ]
Oldenmenger, Wendy H. [3 ]
Kelly, Daniel [4 ]
Kotronoulas, Grigorios [5 ]
机构
[1] European Oncol Nursing Soc EONS, Oncol Adv Nurse Practitioner, Brussels, Belgium
[2] Dublin City Univ, Sch Nursing Psychotherapy & Community Hlth, Dublin, Ireland
[3] Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow City, Scotland
关键词
Patient-reported outcomes; Advanced renal cell carcinoma; Cancer; Advanced hepatocellular carcinoma; Quality of life; Person-centered care; QUALITY-OF-LIFE; CANCER; PROS; CARE;
D O I
10.1016/j.soncn.2023.151409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is little research to help health care professionals understand what patient outcomes are considered a priority in advanced liver or kidney cancer. Knowing what is important to patients can help pro-mote person-centered approaches to treatment and disease management. The aim of this study was to identify those patient-reported outcomes (PROs) that patients, carers, and health care professionals consider as "core" when providing care to those with advanced liver or kidney cancer.Data sources: A three-round Delphi study was undertaken to ask experts by profession or experience to rank PROs identified from a previous literature review. Fifty-four experts, including people living with advanced liver or kidney cancer (44.4%), family members and caregivers (9.3%), and health care professionals (46.8%), reached consensus on 49 PROs including 12 new items (eg, palpitations, hopefulness, or social isolation). Items with the highest rate of consensus included quality of life, pain, mental health, and capacity to do daily activities.Conclusion: People living with advanced liver or kidney cancer experience complex health care needs. Some important outcomes were not actually captured in practice in this population and were suggested as part of this study. There are discrepancies between the views of health care professionals, patients, and family in what is important, highlighting the need of using measures to facilitate communication. Implications for Nursing Practice: Identification of priority PROs reported here will be key to facilitate more focused patient assessments. The actual use of measures in cancer nursing practice to allow monitoring of PROs must be tested for feasibility and usability.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    D Cella
    B Escudier
    B Rini
    C Chen
    H Bhattacharyya
    J Tarazi
    B Rosbrook
    S Kim
    R Motzer
    British Journal of Cancer, 2013, 108 : 1571 - 1578
  • [22] Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
    Staehler, M.
    Motzer, R. J.
    George, D. J.
    Pandha, H. S.
    Donskov, F.
    Escudier, B.
    Pantuck, A. J.
    Patel, A.
    DeAnnuntis, L.
    Bhattacharyya, H.
    Ramaswamy, K.
    Zanotti, G.
    Lin, X.
    Lechuga, M.
    Serfass, L.
    Paty, J.
    Ravaud, A.
    ANNALS OF ONCOLOGY, 2018, 29 (10) : 2098 - 2104
  • [23] Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study
    Matulonis, Ursula A.
    Huang, Helen Q.
    Filiaci, Virginia L.
    Randall, Marcus
    DiSilvestro, Paul A.
    Moxley, Katherine M.
    Fowler, Jeffrey M.
    Powell, Matthew A.
    Spirtos, Nick M.
    Tewari, Krishnansu S.
    Richards, William E.
    Nakayama, John M.
    Mutch, David G.
    Miller, David S.
    Matei, Daniela
    Wenzel, Lari B.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 428 - 436
  • [24] Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
    Munarriz, Javier
    Reynes, Gaspar
    Sanchez-Lorenzo, Luisa
    Esteban, Emilio
    Basterretxea, Laura
    de Avila-Lizarraga, Leticia
    Angel Climent, Miguel
    Jose Juan-Fita, Maria
    Escoin, Corina
    Puente, Javier
    Cassinello, Javier
    Vazquez, Sergio
    Chirivella, Isabel
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 781 - 789
  • [25] Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
    O'Donnell, Peter H.
    Arkenau, Hendrick Tobias
    Sridhar, Srikala S.
    Ong, Michael
    Drakaki, Alexandra
    Spira, Alexander, I
    Zhang, Jingsong
    Gordon, Michael S.
    Degboe, Arnold N.
    Gupta, Ashok K.
    Mukhopadhyay, Pralay
    Huang, Wenmei
    Abdullah, Shaad E.
    Angra, Natasha
    Roskos, Lorin K.
    Guo, Xiang
    Friedlander, Terence
    CANCER, 2020, 126 (02) : 432 - 443
  • [26] Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit
    Dos Santos, M.
    Brachet, P. E.
    Chevreau, C.
    Joly, F.
    CANCER TREATMENT REVIEWS, 2017, 53 : 53 - 60
  • [27] Patient-Reported Outcomes for Determining Prognostic Groups in Veterans With Advanced Cancer
    Chang, Victor T.
    Scott, Charles B.
    Gonzalez, Melanie L.
    Einhorn, Jan
    Yan, Houling
    Kasimis, Basil S.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 50 (03) : 313 - 320
  • [28] Feasibility and Utility of Incorporating Patient-Reported Outcomes into Surveillance Strategies for Advanced Lung Cancer
    Cavanna, Luigi
    Citterio, Chiara
    Orlandi, Elena
    PATIENT-RELATED OUTCOME MEASURES, 2020, 11 : 49 - 66
  • [29] Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
    Choueiri, Toni K.
    Tomczak, Piotr
    Park, Se Hoon
    Venugopal, Balaji
    Symeonides, Stefan
    Hajek, Jaroslav
    Ferguson, Thomas
    Chang, Yen-Hwa
    Lee, Jae Lyun
    Haas, Naomi
    Sawrycki, Piotr
    Sarwar, Naveed
    Gross-Goupil, Marine
    Thiery-Vuillemin, Antoine
    Mahave, Mauricio
    Kimura, Go
    Perini, Rodolfo F.
    Saretsky, Todd L.
    Bhattacharya, Rituparna
    Xu, Lei
    Powles, Thomas
    ONCOLOGIST, 2024, 29 (02): : 142 - 150
  • [30] Using Patient-Reported Outcomes to Measure Symptoms in Children With Advanced Cancer
    Montgomery, Kathleen E.
    Raybin, Jennifer L.
    Ward, Jessica
    Balian, Chelsea
    Gilger, Elizabeth
    Murray, Paula
    Li, Zhanhai
    CANCER NURSING, 2020, 43 (04) : 281 - 289